A study led by UCLA's Drs. Robert Prins and Linda Liau, both UCLA Jonsson Comprehensive Cancer Center members, looked at the impact of a combined treatment using a chemotherapy drug
called decitabine and genetically modified immune cells or T cell immunotherapy.
New findings published in the Proceedings of the National Academy of Sciences showed in lab studies that supplementing an epigenetic cancer drug
called decitabine with vitamin C enhanced the drug's ability to impede cancer cell growth and trigger cellular self - destruction in cancer cell lines.